- Home
- AOMR vs ENGN Comparison
AOMR vs ENGN Comparison
Compare AOMR & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOMR
- ENGN
- Stock Information
- Founded
- AOMR 2018
- ENGN 1999
- Country
- AOMR United States
- ENGN Canada
- Employees
- AOMR N/A
- ENGN N/A
- Industry
- AOMR Real Estate Investment Trusts
- ENGN
- Sector
- AOMR Real Estate
- ENGN
- Exchange
- AOMR Nasdaq
- ENGN Nasdaq
- Market Cap
- AOMR 211.5M
- ENGN 191.1M
- IPO Year
- AOMR 2021
- ENGN N/A
- Fundamental
- Price
- AOMR $9.84
- ENGN $4.62
- Analyst Decision
- AOMR Strong Buy
- ENGN Buy
- Analyst Count
- AOMR 6
- ENGN 7
- Target Price
- AOMR $11.25
- ENGN $23.29
- AVG Volume (30 Days)
- AOMR 225.2K
- ENGN 65.1K
- Earning Date
- AOMR 08-05-2025
- ENGN 09-09-2025
- Dividend Yield
- AOMR 12.98%
- ENGN N/A
- EPS Growth
- AOMR N/A
- ENGN N/A
- EPS
- AOMR 1.56
- ENGN N/A
- Revenue
- AOMR $57,661,000.00
- ENGN N/A
- Revenue This Year
- AOMR N/A
- ENGN N/A
- Revenue Next Year
- AOMR $13.75
- ENGN N/A
- P/E Ratio
- AOMR $6.31
- ENGN N/A
- Revenue Growth
- AOMR N/A
- ENGN N/A
- 52 Week Low
- AOMR $7.36
- ENGN $2.65
- 52 Week High
- AOMR $11.51
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- AOMR 57.41
- ENGN 71.54
- Support Level
- AOMR $9.61
- ENGN $4.14
- Resistance Level
- AOMR $9.81
- ENGN $3.89
- Average True Range (ATR)
- AOMR 0.20
- ENGN 0.29
- MACD
- AOMR 0.02
- ENGN 0.09
- Stochastic Oscillator
- AOMR 78.31
- ENGN 82.93
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.